Thymosin Alpha-1

Thymosin Alpha-1 (Tα1) is a naturally occurring 28-amino-acid peptide originally isolated from Thymosin Fraction 5 by Allan Goldstein at the George Washington University. It is produced primarily by thymic epithelial cells and plays a fundamental role in immune system maturation and function. Tα1 is approved as a pharmaceutical drug (Zadaxin) in over 35 countries for the treatment of hepatitis B, hepatitis C, and as an adjunct to chemotherapy and vaccines.

The peptide acts as a biological response modifier, enhancing T-cell function, promoting dendritic cell maturation, and modulating cytokine production. It activates toll-like receptors (TLR2 and TLR9) on innate immune cells, bridging innate and adaptive immunity. Tα1 increases the expression of MHC class I molecules and enhances natural killer cell activity, while also promoting regulatory T-cell function to prevent autoimmune overreaction.

Clinical research spanning decades has demonstrated Tα1's efficacy in chronic hepatitis B treatment (achieving seroconversion rates of 26-40%), improving response rates to cancer immunotherapy, and enhancing vaccine efficacy in immunocompromised patients. It has been studied in over 80 clinical trials worldwide. During the COVID-19 pandemic, several studies explored its use as an immune modulator in severe infections, showing promise in reducing mortality in critically ill patients with lymphopenia.